Breast cancer specific gene 1

Details Breast cancer specific gene 1 Breast cancer specific gene 1

2006-03-07

2006-03-07

Canella, Karen A. (Department: 1642)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S320100, C435S252300, C435S254110, C435S325000, C536S023500, C536S024310

Reexamination Certificate

active

07008778

ABSTRACT:
The present invention relates to a novel BCSG1 protein. In particular, isolated nucleic acid molecules are provided encoding the human BCSG1 protein. BCSG1 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting breast cancer.

REFERENCES:
patent: 6054289 (2000-04-01), Moore
patent: 0 908 727 (1999-04-01), None
Bork, P, “Powers and Pitfalls in Sequence Analysis . . . ”, Genome Research, vol. 10, pp. 398-400, 2000.
Frisch et al, “A soluble Immunoglobulin Variable Domain without a Disulfide Bridge . . . ”, Biol. Chem. Hoppe-Seyler, vol. 375, pp. 353-356, May 1994.
Kim et al, “Restoring allosterism with compensatory mutations in hemoglobin”, PNAS, vol. 91, pp. 11547-11551, Nov. 1994.
Matthews, B., “Genetic and Structural Analysis of the Protein Stability Problem”, in Perspectives in Biochemistry, Ed. Hans Neurath, vol. 1, pp. 6-9, 1989.
Mathews and Van Holde, Biochemistry (Textbook), 2nd edition, pp. 165-171, 1996.
Molecular Biol. of the Cell, 3rd Ed. Brace Albert, Ed. p. 40, 1996.
A. Branch, “A hitchhiker's guide to antisense and nonantisense biochemical pathways”, Hepatology, vol. 24, pp. 1517-1529.
Broaddus et al, “Strategies for the design and delivery of antisense oligonucleotides in central nervous system”, Methods in Enzymology, vol. 314, pp. 121-135.
Burgess et al, “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding growth-factor-1 from its receptor binding activities”, Journal of Cellular Biology, 1990, vol. 11, pp. 2129-2138.
Lazar et al, “Transforming growth factor alpha”, Molecular and Cellular biology, 1988, vol. 8, pp. 1247-1252.
Accession No. AAQ61427, Mar., 1994.
Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd Edition, 1989, pp. 10.27-10.28.
Allred, D.C. et al., “HER-2
euin Node-Negative Breast Cancer: Prognostic Significance of Overexpression Influenced by the Presence of In Situ Carcinoma,”J. Clin. Oncol. 10(4):599-605 (Apr. 1992).
Angerer, L.M. and Angerer, R.C., “In situhybridization to cellular RNA with radiolabelled RNA probes,” in:In situ hydridization: a practical approach, Wilkinson, D.G., Ed., IRL Press at Oxford University Press, Oxford University Press, Oxford and New York; pp. 15-32 (1992).
Bergh, J. et al., “Complete sequencing of thep53gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy,”Nature Med. 1(10):1029-1034 (Oct. 1995).
Chen, Z. and Sager, R., “Differential Expression Human Tissue Factor in Normal Mammary Epithelial Cells and in Carcinomas,”Mol. Med. 1(2):153-160 (Jan. 1995).
Elledge, R.M. et al., “The role and prognostic significance of p53 gene alterations in breast cancer,”Breast Cancer Res. Treatment 27(1/2):95-102 (Jul./Aug. 1993).
Ernster, V.L. et al., “Incidence of and Treatment for Ductal Carcinoma In Situ of the Breast,”JAMA 275(12):913-918 (Mar. 1996).
Fernö, M. et al., “Cathepsin D, Both a Prognostic Factor and a Predictive Factor for the Effect of Adjuvant Tamoxifen in Breast Cancer,”Eur. J. Cancer 30A(14):2042-2048 (Dec. 1994).
Foekens, J.A. et al., “Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer,”J. Natl. Cancer Inst. 87(10):751-756 (May 1995).
Futreal, P.A. et al., “BRCA1Mutations in Primary Breast and Ovarian Carcinomas,”Science 266:120-122 (Oct. 1994).
Gasparini, G. et al., “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,”J. Natl. Cancer Inst. 85(15):1206-1219 (Aug. 1993).
Gasparini, G. et al.,Erratum:“Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,”J. Natl. Cancer Inst. 85(19):1605 (Oct. 1993).
Goldhirsch, A. et al., “Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer,”J. Natl. Cancer Inst. 87(19):1441-1445 (Oct. 1995).
Gusterson, B.A. et al., “Prognostic Importance of c-erbB-2 Expression in Breast Cancer,”J. Clin. Oncol. 10(7):1049-1056 (Jul. 1992).
Harris, A.L. et al., “Breast Cancer Angiogenesis: Therapy Target and Prognostic Factor,”Eur. J. Cancer 31A(5):831-832 (Jun. 1995).
Klijn, J.G.M. et al., “Prognostic Factors and Response to Therapy in Breast Cancer,”Cancer Surveys 18:165-198 (1993).
Liang, P. et al., “Differential Display and Cloning of Messenger RNAs from Human Breast CancerversusMammary Epithelial Cells,”Cancer Res. 52(24):6966-6968 (Dec. 1992).
Manning, D.L. et al., “Differential Expression of Oestrogen Regulated Genes in Breast Cancer,”Acta Oncologica 35(5):641-646 (1995). Presented at the 5th Scandinavian Breast Cancer Symposium, Reykjavik, Iceland, May-Jun. 1994.
Miki, Y. et al., “A Strong Candidate for the Breast and Ovarian Cancer Susceptibility GeneBRCA1,” Science 266:66-71 (Oct. 1994).
Porter-Jordan, K. and Lippman, M.E., “Overview of the Biologic Markers of Breast Cancer,”Hematol. Oncol. Clin. North Am. 8(1):73-100 (Feb. 1994).
Sager, R. et al., “Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene,”FASEB J. 7(10):964-970 (Jul. 1993).
Schena, M. et al., “Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray,”Science 270:467-470 (Oct. 1995).
Steeg, P.S. et al., “Nm23and breast cancer metastasis,”Breast Cancer Res. Treatment 25(2):175-187 (Feb. 1993).
Velculescu, V.E. et al., “Serial Analysis of Gene Expression,”Science 270:484-487 (Oct. 1995).
Watson, M.A. and Fleming, T.P., “Isolation of Differentially Expressed Sequence Tags from Human Breast Cancer,”Cancer Res. 54(17):4598-4602 (Sep. 1994).
Wooster, R. et al., “Localization of a Breast Cancer Susceptibility Gene,BRCA2, to Chromosome 13q12-13,”Science 265:2088-2090 (Sep. 1994).
Zhang, M. et al., “Differential Expression of Elafin in Human Normal Mammary Epithelial Cells and Carcinomas Is Regulated at the Transcriptional Level,”Cancer Res. 55(120):2537-2541 (Jun. 1995).
Zou, Z. et al., “Maspin, a Serpin with Tumor-Supressing Activity in Human Mammary Epithelial Cells,”Science 263:526-529 (Jan. 1994).
Donohue, S.J., et al., “Human Hydroxyindole-0-Methyltransferase: presence of LINE-1 Fragment in a cDNA Clone and Pineal mRNA,”DNA and Cell Biology 12:715-727, Mary Ann Liebert, Inc. Publishers (1993).
NCBI Entrez, GenBank Report, Accession No. M83779, from Donohue, S.J., et al. (1993).
Hayes et al. “Tumor markers for breast cancer: current utilities and future prospects”,Hematology/Oncology Clinics of North America8(3):485-506 (1994).
Ji et al. “Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing”,Cancer Research57(4):759-764 (1997).
Lavedan et al. “Identification, localization and characterization of the human gamma-synuclein gene”,Human Genetics103(1):106-112 (1998).
Lu et al. “Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences”,Oncogene20(37):5173-5185 (2001).
Wu et al. “Stage-specific expression of breast cancer-specific gene gamma-synuclein”,Cancer Epidemiology, Biomarkers and Prevention12(9):920-925 (2003).
European Search Report, Application No. 04 01 4241, dated Dec. 6, 2004.

Affiliated with

Also associated with

Rating

Breast cancer specific gene 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Breast cancer specific gene 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breast cancer specific gene 1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3553949